February 3, 2022
The MMA’s next noon-time forum will examine sodium-glucose cotransporter-2 (SGLT2) inhibitors, a new 'triple play' for diabetes, cardiovascular and kidney diseases. The forum will take place February 9 from noon to 1 p.m.
This forum will review the pharmacology of SGLT2 inhibitors and then discuss the role these drugs play in the management of type 2 diabetes. The evidence for improving cardiorenal outcomes will be presented and recommendations made for the use of these drugs in patients with cardiovascular or renal diseases. The session will conclude with a Q&A panel discussion.
The forum will be moderated by Andrew Olson, MD, and include Anne Bantle, MD, Prabhjot S. Nijjar, MD, and Mark Rosenberg, MD. All faculty for this forum are with the University of Minnesota Medical School.
Learning objectives for the forum include:
Describe the pharmacology of SGLT2 inhibitors and the use of these drugs in the management of type 2 diabetes mellitus.
Appraise the data supporting the cardiorenal protective effects of SGLT2 inhibitors.
Utilize SGLT2 inhibitors in the management of patients with diabetes, cardiovascular or kidney diseases.
To register, click here.
The forum is free to members, $15 for non-members. This forum is being held in partnership with the University of Minnesota.
December 4, 2025
On December 4, Minnesota Management and Budget (MMB) released its budget forecast for the 2026-27 biennium, showing a short-term budget surplus of $2.5 billion for the current biennium, but warned of a long-term $2.96 billion deficit for the 2028-29 biennium.
December 4, 2025
On December 2, the Vaccine Integrity Project (VIP) released a study on the safety, effectiveness, and public health impact of hepatitis B virus (HBV) vaccinations at birth.
December 4, 2025
The Minnesota Department of Commerce (DOC) is now accepting public comments regarding proposed legislation to mandate insurance coverage of certain treatments.